AR029667A1 - Microesfera de liberacion prolongada para administracion inyectable y procedimiento de preparacion - Google Patents

Microesfera de liberacion prolongada para administracion inyectable y procedimiento de preparacion

Info

Publication number
AR029667A1
AR029667A1 ARP010102466A ARP010102466A AR029667A1 AR 029667 A1 AR029667 A1 AR 029667A1 AR P010102466 A ARP010102466 A AR P010102466A AR P010102466 A ARP010102466 A AR P010102466A AR 029667 A1 AR029667 A1 AR 029667A1
Authority
AR
Argentina
Prior art keywords
microphase
preparation procedure
prolonged release
injectable administration
active ingredient
Prior art date
Application number
ARP010102466A
Other languages
English (en)
Original Assignee
Mainelab
Ethypharm Lab Prod Ethiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mainelab, Ethypharm Lab Prod Ethiques filed Critical Mainelab
Publication of AR029667A1 publication Critical patent/AR029667A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Microesferas destinadas a ser administradas por vía inyectable que comprenden un principio activo proteico y un agente de recubrimiento del principio activo, destinado a prolongar su liberacion, desprovistas de cualquier vestigio de solvente orgánico, y susceptibles de ser obtenidas segun un procedimiento de recubrimiento que implica la puesta en contacto bajo agitacion del principio activo y del agente de recubrimiento en un fluido supercrítico, siendo dicho agente de recubrimiento soluble en el fluido supercrítico. EL principio activo proteico no está desnaturalizado.
ARP010102466A 2000-05-23 2001-05-23 Microesfera de liberacion prolongada para administracion inyectable y procedimiento de preparacion AR029667A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0006587A FR2809309B1 (fr) 2000-05-23 2000-05-23 Microspheres a liberation prolongee pour administration injectable

Publications (1)

Publication Number Publication Date
AR029667A1 true AR029667A1 (es) 2003-07-10

Family

ID=8850528

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102466A AR029667A1 (es) 2000-05-23 2001-05-23 Microesfera de liberacion prolongada para administracion inyectable y procedimiento de preparacion

Country Status (18)

Country Link
US (1) US20040043076A1 (es)
EP (1) EP1303259B1 (es)
JP (1) JP2003534267A (es)
KR (1) KR100787669B1 (es)
CN (1) CN1438877A (es)
AR (1) AR029667A1 (es)
AU (2) AU2001263996B2 (es)
BR (1) BR0111054A (es)
CA (1) CA2410219A1 (es)
ES (1) ES2413406T3 (es)
FR (1) FR2809309B1 (es)
HU (1) HU228702B1 (es)
IL (2) IL153046A0 (es)
MX (1) MXPA02011560A (es)
NO (1) NO333742B1 (es)
TW (1) TWI264310B (es)
WO (1) WO2001089481A1 (es)
ZA (1) ZA200209553B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
EP1197513B1 (en) 2000-10-10 2005-03-30 Kao Corporation Process for preparing composite particles
WO2002043580A2 (en) 2000-10-27 2002-06-06 Epic Therapeutics, Inc. Production of microspheres
ATE395042T1 (de) * 2001-08-16 2008-05-15 Baxter Int Darreichungsformen welche mikropartikel und treibgas enthalten
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
GB0205868D0 (en) * 2002-03-13 2002-04-24 Univ Nottingham Polymer composite with internally distributed deposition matter
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US8075919B2 (en) * 2003-07-18 2011-12-13 Baxter International Inc. Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
AU2004258971A1 (en) * 2003-07-22 2005-02-03 Baxter Healthcare S.A. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
MXPA06001353A (es) 2003-08-08 2006-05-04 Abgenix Inc Anticuerpos dirigidos a hormona paratiroides(pth) y usos de los mismos.
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
KR100603974B1 (ko) * 2003-12-05 2006-07-25 김갑식 고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법
FR2868704B1 (fr) * 2004-04-07 2007-09-14 Ethypharm Sa Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
CA2566075A1 (en) 2004-05-12 2005-12-01 Baxter Healthcare S.A. Microspheres comprising protein and showing injectability at high concentrations of said agent
ES2442115T3 (es) * 2004-05-12 2014-02-10 Baxter International Inc. Microesferas que contienen oligonucleótidos, su utilización para la preparación de un medicamento para el tratamiento de la diabetes tipo 1
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
ES2422757T3 (es) * 2004-05-12 2013-09-13 Baxter Int Uso terapéutico de microesferas de ácido nucleico
US7390097B2 (en) * 2004-08-23 2008-06-24 3M Innovative Properties Company Multiple channel illumination system
FR2874836B1 (fr) * 2004-09-09 2007-04-27 Pierre Fabre Medicament Sa Procede d'enrobage de poudres
AU2005308133B2 (en) * 2004-11-29 2008-10-16 Japan Science And Technology Agency Method for preparing composite fine particles
CN101188996B (zh) * 2005-04-27 2013-03-27 巴克斯特国际公司 表面改性的微粒及其形成和使用方法
US8475845B2 (en) * 2005-07-15 2013-07-02 Map Pharmaceuticals, Inc. Method of particle formation
CA2615378C (en) * 2005-07-15 2015-02-17 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
US7964574B2 (en) * 2006-08-04 2011-06-21 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
WO2008060786A2 (en) * 2006-10-06 2008-05-22 Baxter International Inc. Microencapsules containing surface-modified microparticles and methods of forming and using the same
AU2008242842B2 (en) * 2007-04-17 2014-06-05 Baxter Healthcare Sa Nucleic acid microparticles for pulmonary delivery
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
CA2743789C (en) * 2008-11-16 2017-10-31 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
EP2353588B1 (en) * 2010-01-21 2015-04-15 Agricultural Technology Research Institute A sustained release preparation of factor IX
KR101156094B1 (ko) * 2010-02-22 2012-06-20 경상대학교산학협력단 약물송달을 위한 양친성 ＰＨＡ－ｍＰＥＧ 공중합 나노 컨테이너
WO2013075068A1 (en) 2011-11-18 2013-05-23 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
CN102552169B (zh) * 2012-02-17 2015-07-29 深圳市健元医药科技有限公司 一种醋酸阿肽地尔缓释微球制剂及其制备方法
KR101421343B1 (ko) * 2012-08-21 2014-07-18 경상대학교산학협력단 폴리(4-하이드록시부티레이트)-ｂ-모노메톡시(폴리에틸렌글리콜) 공중합체 나노입자, 이의 제조방법 및 이를 유효성분으로 함유하는 뇌질환 치료용 약학적 조성물
WO2014051251A1 (en) * 2012-09-28 2014-04-03 Industrial Cooperation Foundation Chonbuk National University Pvax copolymer and pvax microparticles comprising the same
CN102921011B (zh) * 2012-11-09 2014-10-15 东华大学 一种仿血细胞形貌温敏聚合物微球及其制备方法
GB201317756D0 (en) * 2013-10-08 2013-11-20 Critical Pharmaceuticals Ltd New process
US10258588B2 (en) * 2013-12-31 2019-04-16 Pb&B Sa Controlled release fatty acid compositions for use in body reconstruction and body-shaping
CN104474533A (zh) * 2014-11-24 2015-04-01 华南理工大学 一种可用于创面修复的复合微球的制备方法
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN108042793B (zh) * 2017-11-13 2020-07-07 中国人民解放军第四军医大学 包埋gdnf的多核-单壳微球缓释系统的制备方法
WO2020038298A1 (zh) * 2018-08-20 2020-02-27 中国科学院过程工程研究所 一种基于微囊的疫苗
CN110585055B (zh) * 2019-08-26 2023-06-13 武汉贝缇安卡医疗健康投资有限公司 AcSDKP在增加成纤维细胞分泌Ⅲ型胶原蛋白含量的应用
CN114209887B (zh) * 2021-08-24 2023-03-03 杭州协合医疗用品有限公司 一种含可控降解聚酯微球的注射用凝胶

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE74009T1 (de) * 1986-08-11 1992-04-15 American Cyanamid Co Zusammensetzungen zur parenteralen verabreichung und deren verwendung.
EP0706821A1 (en) * 1994-10-06 1996-04-17 Centre De Microencapsulation Method of coating particles
PT814778E (pt) * 1995-03-10 2001-11-30 Roche Diagnostics Gmbh Formas de administracao farmaceuticas contendo polipeptidos sob a forma de microparticulas e processo para a sua preparacao
FR2753639B1 (fr) * 1996-09-25 1998-12-11 Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede
US5766637A (en) * 1996-10-08 1998-06-16 University Of Delaware Microencapsulation process using supercritical fluids
EP0954282B1 (en) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO2000004916A1 (en) * 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
EP1107743B1 (en) * 1998-08-25 2007-06-27 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2797398B1 (fr) * 1999-08-11 2002-10-18 Mainelab Microparticules pour administration pulmonaire
AU2729101A (en) * 1999-12-21 2001-07-03 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
EP1246609B1 (en) * 2000-01-14 2010-03-31 Brown University Research Foundation Process for making micronized freeze-dried particles
WO2001085136A2 (en) * 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery

Also Published As

Publication number Publication date
EP1303259B1 (fr) 2013-03-20
US20040043076A1 (en) 2004-03-04
IL153046A (en) 2013-12-31
FR2809309B1 (fr) 2004-06-11
AU6399601A (en) 2001-12-03
NO20025552D0 (no) 2002-11-19
BR0111054A (pt) 2003-04-15
WO2001089481A1 (fr) 2001-11-29
HUP0302012A3 (en) 2005-11-28
KR20030011858A (ko) 2003-02-11
FR2809309A1 (fr) 2001-11-30
HUP0302012A2 (hu) 2003-09-29
TWI264310B (en) 2006-10-21
CA2410219A1 (fr) 2001-11-29
JP2003534267A (ja) 2003-11-18
CN1438877A (zh) 2003-08-27
HU228702B1 (en) 2013-05-28
MXPA02011560A (es) 2004-09-10
KR100787669B1 (ko) 2007-12-21
EP1303259A1 (fr) 2003-04-23
AU2001263996B2 (en) 2006-01-19
ES2413406T3 (es) 2013-07-16
ZA200209553B (en) 2003-08-26
IL153046A0 (en) 2003-06-24
NO333742B1 (no) 2013-09-02
NO20025552L (no) 2003-01-20

Similar Documents

Publication Publication Date Title
AR029667A1 (es) Microesfera de liberacion prolongada para administracion inyectable y procedimiento de preparacion
AR048017A1 (es) Composicion y metodo para aumentar la biodisponibilidad
DK1299108T3 (da) Parasiticidt præparat samt fremgangsmåde til fremstilling af dette præparat
AR045068A1 (es) Formulacion de liberacion inmediata de composiciones farmaceuticas
WO2006129161A3 (en) Vitamin formulation
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
DK1333880T3 (da) Indretninger med coatede mikrofremspring til medikamentafgivelse gennem huden
ATE429416T1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
AR030253A1 (es) Sistemas de suministro de drogas autoemulsionantes para drogas lipofilicas extremadamente insolubles en agua, una formulacion y el uso de una composicion para la fabricacion de un medicamento
ATE424816T1 (de) Zubereitungen für die topische anwendung und verfahren zur abgabe eines wirkstoffs an ein substrat
AR052545A1 (es) Suspension no acuosa inyectable
CO6270303A2 (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
UY30587A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasa s janus
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
AR046878A1 (es) Agente endoparasiticida para administracion topica
DE60134245D1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
CO6361907A2 (es) Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo
ATE332125T1 (de) Emulsionen für in-situ arzneistoffabgabesysteme
CL2004001255A1 (es) Formulacion liquida herbicida que contiene (a) uno o mas derivados de acidos policarboxilicos y (b) uno o mas compuestos activos inhibidores de als, procedimiento de para preparar la formulacion que comprende el mezclado de los componentes y metodo p
AR018607A1 (es) Preparacion farmaceutica que en calidad de ingrediente activo contiene levotiroxina sodica, y un procedimiento para su preparacion
BR0311687A (pt) composições farmacêuticas estabilizadas com base em óleo de rìcino polioxietilado e método para a fabricação das mesmas
CU22836A3 (es) Sistema de gel de nimesulida para uso tópico
DOP2010000117A (es) Producto de dispersion solida de drogas basadas en n-aril urea
UY27341A1 (es) Formulación farmacéutica de sabor enmascarado y procedimiento para su preparación.
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler

Legal Events

Date Code Title Description
FA Abandonment or withdrawal